Obsidian Therapeutics (NASDAQ:OBX) Now Covered by Lifesci Capital

Lifesci Capital assumed coverage on shares of Obsidian Therapeutics (NASDAQ:OBX) in a report issued on Tuesday,Benzinga reports. The firm set an “outperform” rating and a $43.00 price target on the stock. Lifesci Capital’s price objective would indicate a potential upside of 145.29% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Piper Sandler started coverage on shares of Obsidian Therapeutics in a report on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price target on the stock. TD Cowen started coverage on shares of Obsidian Therapeutics in a research report on Thursday, August 6th. They set a “buy” rating for the company. Finally, Zacks Research raised shares of Obsidian Therapeutics to a “hold” rating in a report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Obsidian Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $42.50.

Obsidian Therapeutics Price Performance

Obsidian Therapeutics stock opened at $17.53 on Tuesday. Obsidian Therapeutics has a twelve month low of $14.57 and a twelve month high of $49.97.

About Obsidian Therapeutics

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.